AstraZeneca PLC (AZN.L)
24 Jun 2016
Latest Key Developments (Source: Significant Developments)
EU Medicines Agency : EU Medicines Agency recommendations for May 2016 . Recommends against approval of Takeda Pharmaceutical Co Ltd's <4502.T> ixazomib to treat multiple myeloma . Recommends approval of AstraZeneca Plc's
Orexo AB:Says AstraZeneca acquires all rights to Orexo's OX-CLI project.Says in accordance to option agreement from 2013, Orexo will receive a payment of $5 million for rights to OX-CLI.Says future milestone payments can be expected when OX-CLI meets defined development and commercial objectives.Says in addition to milestones Orexo will receive a tiered single digit royalty on future net-revenue. Full Article
AstraZeneca:FDA approves new indication for FASLODEX (fulvestrant).US FDA approved a new indication expanding the use of FASLODEX to include use in combination with palbociclib. Full Article
AstraZeneca Plc: :AstraZeneca enters into agreement with Prostrakan for rights to moventig in Europe.Has entered into an agreement with Prostrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for rights to moventig (naloxegol) in European Union (eu), Iceland, Norway, Switzerland and Liechtenstein .Moventig is first once-daily, oral peripherally-acting mu-opioid receptor antagonist (pamora) approved in Europe for treatment of opioid-induced constipation (oic) in adult patients who have had an inadequate response to laxative(s) .Under terms of agreement, Prostrakan will make an upfront payment to AstraZeneca of $70 million, to acquire rights to sell and develop moventig in EU, Iceland, Norway, Switzerland and Liechtenstein .Prostrakan will make additional payments contingent on market access decisions in certain European markets, and will pay AstraZeneca tiered double-digit royalties on sales as well as sales milestones.Transaction does not include transfer of any AstraZeneca employees or facilities. Moventig is available in UK, Ireland, Germany, Nordics, Austria and Switzerland. Full Article
LONDON/CHICAGO - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the nasal spray vaccine is not effective at preventing influenza.